To assess the prognostic utility of conventional biochemical and imaging response criteria and 68Ga- prostate-specific membrane antigen (PSMA) 11 PET adapted or specific systems regarding overall survival (OS) in men with metastatic hormone-sensitive (mHSPC) and castration-resistant PC (mCRPC) treated with taxane-based chemotherapy.
Methods: A total of 103 patients (pts) (n = 57 mHSPC, n = 46 mCRPC) underwent taxane-based chemotherapy. All patients had a minimum of two PSMA PET scans (at baseline and up to 3 months post-treatment). PSMA PET response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1), adapted Prostate Cancer Working Group Criteria 3 (aPCWG3, using PSMA PET instead of bone scan), adapted Positron Emission Tomography Response Criteria in Solid Tumors (aPERCIST) and PSMA PET Progression (PPP) criteria. Response by each criterion was stratified by either progressive disease (PD) versus non-PD. For aPERCIST, stratification by PD, stable disease (SD) and partial/complete remission (PR/CR) was performed. Biochemical response was determined by PSA decline ≥50%. Subgroup analyses were performed by castration-status. Univariable cox proportional hazard regression analyses including Harrell's concordance indices were calculated to investigate the association of PD by response criteria and OS. Kaplan-Meier tests including log-rank statistics were calculated for survival analyses. Results: 26 (25%) of pts had non-measurable disease by RECIST 1.1. PD by any response criterion was associated with an at least 2.5-fold increased risk of death and was highest for PD versus CR/PR by aPERCIST (HR 11.4) on univariable regression. Stratified by castration status, a similar pattern was observed. PD by any criterion as associated with significantly shortened OS across overall and subgroup analyses. PR/CR by aPERCIST identified pts with lower risk of death and longer OS as compared to patients with PD or SD. Conclusion: 68Ga-PSMA11 PET-based response criteria (PPP, aPERCIST, aPCWG3) have high prognostic utility in men with metastatic PC undergoing taxane-based chemotherapy. PPP is simple to use, identified most patients with PD and showed best prognostic utility regarding OS. PR/CR by aPERCIST identifies a subgroup of responders (PR/CR) showing better outcomes than patients with PD or SD. Future studies are warranted to amend the current paradigm relying on mere differentiation of PD versus non-PD in metastatic PC and to identify true treatment responders by imaging criteria.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2022 Dec 29 [Epub ahead of print]
Lukas Lunger, Maythinee Chantadisai, Amir Karimzadeh, Isabel Rauscher, Calogero D'Alessandria, Benedikt Feuerecker, Thomas Langbein, Robert Tauber, Stefan Schiele, Wolfgang Andreas Weber, Matthias Eiber
Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Germany., Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Thailand., Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Germany.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/36581373
Related Content:
Exploring PSMA PET-Based Response's Prognostic Role in Prostate Cancer Treatment, Journal Club - Rashid Sayyid & Zachary Klaassen